{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:30:07Z","timestamp":1794839407020,"version":"4.9.1"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Suzetrigine is a non-opioid, highly selective Na\n                      <jats:sub>V<\/jats:sub>\n                      1.8 pain-signal inhibitor of the voltage-gated sodium channel Na\n                      <jats:sub>V<\/jats:sub>\n                      1.8, with no addiction potential approved in the US for moderate-to-severe acute pain in January 2025.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this phase 4, single-arm study, suzetrigine was administered as part of multimodal therapy (MMT;100-mg preoperatively, then 50-mg q12h) for \u226414days. Patients underwent aesthetic\/reconstructive surgeries wherein opioids are commonly used \u226572h postoperatively. Investigators determined MMT, with acetaminophen and\/or ibuprofen recommended. The primary endpoint was proportion of patients reporting good\/very good\/excellent on a patient global assessment (PGA) for pain control at end of treatment. Opioid-rescue and safety were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Patients (N=99) underwent various procedures, the most common being aesthetic and reconstructive breast procedures (33.3% and 13.1%, respectively), abdominoplasty with liposuction (28.3%), and turbinoplasty (13.1%). Most patients (90.7%) rated suzetrigine as part of MMT as good\/very good\/excellent on a PGA for pain control at end of treatment, which was consistently high across surgeries. Most patients (90.9%) did not require opioid-rescue; those who did received 2.4 tablets (mean) after surgery (mean:2.0days). Most common MMT was suzetrigine with only acetaminophen and\/or ibuprofen (78.8%), while 12.1% used suzetrigine alone. Suzetrigine was safe and well-tolerated. Adverse events were consistent with postoperative settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Suzetrigine demonstrated highly effective pain management and enabled opioid-free recovery for most patients (90.9%) when initiated preoperatively and as part of MMT in aesthetic and reconstructive surgeries wherein opioids are commonly used postoperatively; in contrast, in studies of mixed cosmetic procedures in the literature, &lt;10% did not require opioids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/prs.0000000000013299","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:01:28Z","timestamp":1784322088000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Suzetrigine as Part of Multimodal Therapy Enables Opioid-Free Recovery After Aesthetic or Reconstructive Procedures"],"prefix":"10.1097","author":[{"given":"Samuel J.","family":"Lin","sequence":"first","affiliation":[{"name":". Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"McCoun","sequence":"additional","affiliation":[{"name":". CenExel ACMR Clinical Research, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daneshvari","family":"Solanki","sequence":"additional","affiliation":[{"name":". HD Research, LLC, Bellaire, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Mehta","sequence":"additional","affiliation":[{"name":". Vertex Pharmaceuticals, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bortcosh","sequence":"additional","affiliation":[{"name":". Vertex Pharmaceuticals, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanju","family":"Zhang","sequence":"additional","affiliation":[{"name":". Vertex Pharmaceuticals, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin J.","family":"Correll","sequence":"additional","affiliation":[{"name":". Vertex Pharmaceuticals, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Scranton","sequence":"additional","affiliation":[{"name":". Vertex Pharmaceuticals, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bertoch","sequence":"additional","affiliation":[{"name":". CenExel JBR Clinical Research, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,6]]},"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000013299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:01:28Z","timestamp":1784322088000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000013299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000013299","relation":{},"ISSN":["0032-1052","1529-4242"],"issn-type":[{"value":"0032-1052","type":"print"},{"value":"1529-4242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}